<DOC>
	<DOCNO>NCT00158496</DOCNO>
	<brief_summary>Chronic hepatitis C liver disease relate virus : hepatitis C virus ( HCV ) . The type HCV present Egypt ( genotype 4 ) , reputation respond poorly Interferon treatment chronic stage . Pegylated Interferon new form Interferon stay body long time allow patient take less injection per week . It prove effective standard Interferon . The combination two drug , Interferon Ribavirin , consider best treatment available chronic hepatitis C .</brief_summary>
	<brief_title>Chronic Hepatitis C Treatment Pegylated Interferon Ribavirin Naive Egyptian Patients ( ANRS 1211 )</brief_title>
	<detailed_description>Egypt country high HCV prevalence worldwide , number infect Egyptians estimate around 8 million . The HCV genotype circulate Egypt genotype 4 . This genotype reputation , base available data , respond poorly treatment . This study estimate safety efficacy combination peg-IFNα-2a plus Ribavirin , Egyptian patient chronic hepatitis C. This treatment chosen base well expect efficacy compare pegylated interferon alone . The primary objective study ass efficacy tolerance combination pegylated interferon ( peg-IFNα-2a ) plus ribavirin Egyptian patient chronic hepatitis C prior treatment HCV . Methods : Open trial . Follow-up duration : 72 week . Enrolment duration : 18 month . Total trial duration : 3 year half , include trial analysis ( carry 6 month follow follow-up completion last patient ) . Total number patient : 100 . Precision around expect efficacy rate ( 40 % intention-to-treat analysis ) : 9.6 % . Treatment strategy : Peg-IFNα-2a 180microg/week 48 week , Ribavirin least 11 mg/kg/day 48 week Main inclusion criterion : HCV RNA positive PCR ; METAVIR score : &gt; A2 &gt; = F1 &gt; = A1 &gt; F2 ; ALAT 1.5*N ; prior treatment IFNalpha , PEG-IFNalpha ribavirin Main exclusion criterion : Liver disease hepatitis C ; advance liver disease ; negative HCV RNA . Patient cohort follow-up conducted village rural Egypt High HCV prevalence ( Menoufia governorate ) propose participate trial . Pre-enrolment investigation , liver biopsy , patient follow-up carry local hospital . Blood test analysis carry responsibility Hepatitis Virology Reference Laboratory National Hepatology Tropical Medicine Institute , Cairo ; trial monitoring carry Department Community Medicine Ain Shams ; methodological assistance “ Unite des Maladies Emergentes ” Pasteur Institute INSERM U444 , Paris . Treatment patient HCV RNA qualitative PCR still positive 24 week combination Peg-IFNα-2a ribavirin , stop .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>HCV antibody use third generation test HCV RNA positive PCR Liver biopsy past 18 month METAVIR score A2 equal F1 , equal A1 F2 ALT 1.5 time normal range 24 week prior inclusion ( Week28 ; W2 ) ; Patients never treat ribavirin , IFNalpha PEGIFNalpha Normal albumin Prothrombin time equal 60 percent Normal bilirubin Alphafoetoprotein equal 3 time normal range laboratory HBs antigen negative Two negative Kato test ( S.mansoni ) three day apart Hemoglobin equal 11g/dl , Leucocytes equal 3000/mm3 Neutrophils equal 1500/mm3 Platelets equal 100 000/mm3 Blood creatinin equal 150 micromol/l Normal TSH Antinuclear antibodies 1/160 Fasting blood sugar 70115mg/dl ( glucose intolerance diabetes : HbA1C &lt; = 8,5 % ) Normal ophthalmologic examination patient history blood pressure and/or diabetes Effective contraception treatment period No breastfeeding study period . Signed informed consent Coinfection hepatitis B ( positive HBs antigen ) Hemochromatosis Alpha1 antitrypsin deficiency Wilson disease Alcoholismrelated liver disease Gilbert disease Alcohol intake 50g/day male 40 g/day female Ongoing intravenous drug use Aggravated liver cirrhosis ( history presence ascitis , oesophageal varicosis , liver encephalopathy ) Hepatocellular carcinoma Psychiatric disease : history severe nervous breakdown severe psychiatric disease major psychosis , suicidal idea , suicide attempts… Epilepsy Autoimmune disease Heart disease six month precede enrolment – patient significant change EKG Uncontrolled diabetes Chronic respiratory insufficiency hypoxemia &lt; 10 kPa Medical surgical condition , nonstabilised , life expectancy low two year . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Genotype 4</keyword>
	<keyword>Pegylated Interferon</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Egypt</keyword>
</DOC>